BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KST-6051 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of KST-6051\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07458347-2585@assetmemo.bio
DTSTAMP:20261121T005649Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:KST-6051: Phase 1 readout est. (NCT07458347)
DESCRIPTION:KST-6051\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Phas
 e 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants W
 ith Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog 
 (KRAS) Mutation\nEstimated primary completion: April 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/kst-6051#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07458347
URL:https://assetmemo.bio/drug/kst-6051#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
